(Q43549877)

24 November 2017

title

Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer (English)

1 reference

24 November 2017

2

1 reference

24 November 2017

1

Karin Milde-Langosch

1 reference

24 November 2017

4

Isabell Witzel

1 reference

24 November 2017

Volkmar Müller

3

1 reference

24 November 2017

Achim Rody

series ordinal

5

1 reference

24 November 2017

Markus Schmidt

series ordinal

6

1 reference

24 November 2017

Ralph M Wirtz

series ordinal

7

1 reference

24 November 2017

language of work or name

English

0 references

publication date

8 November 2012

1 reference

Breast Cancer Research and Treatment

24 November 2017

published in

1 reference

24 November 2017

volume

137

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

57-67

1 reference

24 November 2017

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Measuring proliferation in breast cancer: practicalities and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Proliferation marker Ki-67 in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Ki67 in breast cancer: prognostic and predictive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Phosphorylation by Aurora B Converts MgcRacGAP to a RhoGAP during Cytokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing signal-containing nuclear chaperone in the activation of STAT transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Identification of genes correlated with early-stage bladder cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2296-X

10.1007/S10549-012-2296-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

24 November 2017

1023206132

0 references

Fatcat ID

release_3253fy56xbfgtbzrjoikc5myru

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3253fy56xbfgtbzrjoikc5myru

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference